Pharma major Novartis falls 9% after three drug trial setbacks
Novartis shares fell 8.9% after its del-desiran drug failed a late-stage trial for muscle-wasting disorder, marking the third setback in a week. The company also faces doubts about its growth targets and the $12B Avidity acquisition, according to analysts.
How this was made
The 30-second read
Why it matters
The negative trial data erodes confidence in the neuromuscular pipeline and casts doubt on the $12 bn Avidity acquisition, prompting a sharp share decline.
Market read
The news drives immediate sell pressure in a large‑cap pharma stock and may affect sector sentiment across global health‑care indices.
What to watch
The failure may accelerate M&A activity, potentially unlocking value if a strategic partner steps in.
Background
Novartis disclosed a late‑stage trial failure for del‑desiran, its third setback in a week, after earlier failures of pelacarsen and a pause of rap‑cel trials.
Ticker impact
Novartis shares fell about 9% after its del-desiran drug failed a late‑stage trial for myotonic dystrophy.
Further downside pressure likely if no remedial data emerges.
A 9% drop on the day signals strong sell pressure; analysts already question growth without M&A.
Market effects
Neuromuscular biotech segment faces heightened risk perception; peers may see valuation pressure.
Swiss market likely drags lower as the headline Swiss pharma stock declines.
Large‑cap pharma news can influence global health‑care indices and risk‑off sentiment.
Counterpoint
If the company can offset the setback with its successful remibrutinib data, the sell‑off may be overdone.
Key entities
- companyNovartis
Swiss pharmaceutical giant, ticker NVS.
- drugdel‑desiran
Antibody‑oligonucleotide conjugate for myotonic dystrophy.
